Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

ClinicalTrials.gov ID: NCT03703882

Public ClinicalTrials.gov record NCT03703882. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The PolarisDMD study is a Phase 3, global study to evaluate the efficacy and safety of edasalonexent in pediatric patients with a genetically confirmed diagnosis of DMD. Male patients from 4-7 years of age (up to 8th birthday) will be enrolled. Edasalonexent is an orally administered small molecule that inhibits NF-kB, which is the key link between loss of dystrophin and disease pathology and plays a fundamental role in the initiation and progression of skeletal and cardiac muscle disease in DMD.

Study identification

NCT ID
NCT03703882
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Catabasis Pharmaceuticals
Industry
Enrollment
131 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
4 Years to 7 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 1, 2018
Primary completion
Sep 21, 2020
Completion
Sep 21, 2020
Last update posted
Jun 20, 2022

2018 – 2020

United States locations

U.S. sites
24
U.S. states
19
U.S. cities
23
Facility City State ZIP Site status
Arkansas Children's Hospital Little Rock Arkansas 72202
Children's Hospital of Los Angeles Los Angeles California 90027
UC Davis Sacramento California 95817
Nemours Children's Hospital Orlando Florida 32827
Rare Disease Research, LLC Atlanta Georgia 30318
Rush University Children's Hospital Chicago Illinois 60612
University of Iowa Children's Hospital Iowa City Iowa 52242
University of Kansas Medical Center Fairway Kansas 66205
Kennedy Krieger Institute Baltimore Maryland 21205
Johns Hopkins School of Medicine Baltimore Maryland 21287
Boston Children's Hospital Boston Massachusetts 02115
University of Michigan Ann Arbor Michigan 48109
University of Minnesota Minneapolis Minnesota 55455
Las Vegas Clinic Las Vegas Nevada 89145
Cincinnati Children's Hospital Cincinnati Ohio 45229
MetroHealth Medical Center Cleveland Ohio 44109
Shriners Hospitals for Children Portland Oregon 97239
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
Vanderbilt University Medical Center Nashville Tennessee 37212
Cook Children's Medical Center Fort Worth Texas 76104
University of Texas Health Science Center at San Antonio San Antonio Texas 78229
University of Utah Salt Lake City Utah 84112
Children's Hospital of the King's Daughters Norfolk Virginia 23510
Children's Hospital of Richmond at VCU Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03703882, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 20, 2022 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03703882 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →